Am J Arthritis | Volume 1, Issue 2 | Case Report | Open Access

Adult Familial Mediterranean Fever Treated with Canakinumab

Mustafa Al Izzi^*

Mediclinic Welcare Hospital, Al Garhoud, Dubai

^*Correspondance to: Mustafa Al Izzi 

Fulltext PDF

Abstract

Familial mediterranean fever (FMF), the most common form of hereditary auto inflammatory disorders, characterized by recurrent attacks of fever with serosal or synovial inflammation. Colchicine, the standard of care for patients with FMF, considered as safe, cheap and effective remedy in the majority of the patients for reducing both the frequency of the inflammatory episodes and the risk of developing amyloidosis. Several reports of patients with FMF being successfully treated with agents blocking IL-1 activity, initially with daily injections of the recombinant form of IL-1 receptor antagonist (IL-1Ra), Anakinra and more recently with canakinumab which is a fully human immunoglobulin G (IgG) antibody directed against IL-1β. This is a case report for an adult male patient with FMF treated successfully with canakinumab.

Keywords:

Familial mediterranean fever (FMF); Interleukin-1 (IL-1)

Citation:

Al Izzi M. Adult Familial Mediterranean Fever Treated with Canakinumab. Am J Arthritis. 2017;1(2):1008.